Opiant Pharmaceuticals Inc (NASDAQ:OPNT) Insider Phil Skolnick Sells 10,000 Shares

Share on StockTwits

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) insider Phil Skolnick sold 10,000 shares of the stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $15.80, for a total transaction of $158,000.00.

Phil Skolnick also recently made the following trade(s):

  • On Thursday, October 3rd, Phil Skolnick sold 10,000 shares of Opiant Pharmaceuticals stock. The shares were sold at an average price of $14.68, for a total transaction of $146,800.00.
  • On Wednesday, September 4th, Phil Skolnick sold 10,000 shares of Opiant Pharmaceuticals stock. The shares were sold at an average price of $14.15, for a total transaction of $141,500.00.

Shares of OPNT traded up $0.38 during mid-day trading on Friday, reaching $15.80. 6,400 shares of the company’s stock were exchanged, compared to its average volume of 20,137. The company has a market cap of $61.02 million, a price-to-earnings ratio of -2.23 and a beta of 0.31. The company has a 50-day simple moving average of $15.06 and a two-hundred day simple moving average of $13.47. Opiant Pharmaceuticals Inc has a 52-week low of $9.98 and a 52-week high of $17.02.

Opiant Pharmaceuticals (NASDAQ:OPNT) last announced its quarterly earnings results on Thursday, August 8th. The technology company reported $0.31 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.86. The company had revenue of $6.78 million for the quarter, compared to analyst estimates of $3.91 million. Opiant Pharmaceuticals had a negative net margin of 11.78% and a negative return on equity of 12.74%. On average, equities research analysts predict that Opiant Pharmaceuticals Inc will post 1.05 EPS for the current fiscal year.

A number of research analysts have issued reports on the stock. TheStreet raised shares of Opiant Pharmaceuticals from a “d” rating to a “c-” rating in a report on Friday, August 30th. Northland Securities reaffirmed a “buy” rating and issued a $42.00 target price on shares of Opiant Pharmaceuticals in a report on Thursday.

Institutional investors and hedge funds have recently made changes to their positions in the business. Advisor Group Inc. boosted its holdings in shares of Opiant Pharmaceuticals by 24.3% in the 2nd quarter. Advisor Group Inc. now owns 4,600 shares of the technology company’s stock valued at $61,000 after purchasing an additional 900 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Opiant Pharmaceuticals by 93.5% during the 2nd quarter. BlackRock Inc. now owns 20,792 shares of the technology company’s stock valued at $276,000 after acquiring an additional 10,045 shares in the last quarter. Morgan Stanley lifted its holdings in shares of Opiant Pharmaceuticals by 1,000.3% during the 2nd quarter. Morgan Stanley now owns 22,414 shares of the technology company’s stock valued at $297,000 after acquiring an additional 20,377 shares in the last quarter. Wedge Capital Management L L P NC acquired a new position in shares of Opiant Pharmaceuticals during the 3rd quarter valued at $363,000. Finally, Stonepine Capital Management LLC lifted its holdings in shares of Opiant Pharmaceuticals by 7.0% during the 2nd quarter. Stonepine Capital Management LLC now owns 315,468 shares of the technology company’s stock valued at $4,180,000 after acquiring an additional 20,574 shares in the last quarter. Institutional investors own 20.82% of the company’s stock.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.

Featured Story: Earnings Reports

Insider Buying and Selling by Quarter for Opiant Pharmaceuticals (NASDAQ:OPNT)

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.